Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Parvalbumins are small, well-conserved calcium-binding proteins (EF-hand proteins) found in the skeletal muscle of most fish species, including bluefish[2][3]. They are challenging allergens because they display high cross-reactivity between species. Allergic reactions occur due to IgE recognition of either species-conserved or species-specific epitopes in parvalbumin. The protein’s structure and its metal (calcium) binding influence allergenicity and immune recognition[2][4]. Parvalbumins trigger IgE-mediated hypersensitivity responses and are the main reason for fish allergy and anaphylactic reactions to fish consumption. No pharmacological interventions directly target parvalbumin; diagnosis and management rely on allergy testing and dietary avoidance. Parvalbumin is not a therapeutic target in the formal sense, and "bluefish allergens" as a descriptor is non-specific—parvalbumin should be specified for clarity and structured data purposes[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Parvalbumin.